564 related articles for article (PubMed ID: 33347998)
21. ZILVERPASS Study: ZILVER PTX Stent vs. Bypass Surgery in Femoropopliteal Lesions, 3 year results and economic analysis.
Bosiers M; DE Donato G; Torsello G; Galvagni Silveira P; Deloose K; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Callaert J; Eckstein HH; Tessarek J; Giaquinta A; van den Eynde W; Verbist J; Wahl-Gravsen J; Bosiers MJ
J Cardiovasc Surg (Torino); 2023 Aug; 64(4):413-421. PubMed ID: 37162238
[TBL] [Abstract][Full Text] [Related]
22. ZILVERPASS Study: ZILVER PTX Stent versus Prosthetic Above-the-Knee Bypass Surgery in Femoropopliteal Lesions, 5-year Results.
Bosiers MJ; De Donato G; Torsello G; Silveira PG; Scheinert D; Veroux P; Hendriks J; Maene L; Keirse K; Navarro T; Eckstein HH; Teβarek J; Giaquinta A; van den Eynde W; Verbist J; Callaert J; Deloose K; Bosiers M
Cardiovasc Intervent Radiol; 2023 Oct; 46(10):1348-1358. PubMed ID: 37670198
[TBL] [Abstract][Full Text] [Related]
23. Two-Year Efficacy and Safety Results from the IMPERIAL Randomized Study of the Eluvia Polymer-Coated Drug-Eluting Stent and the Zilver PTX Polymer-free Drug-Coated Stent.
Müller-Hülsbeck S; Benko A; Soga Y; Fujihara M; Iida O; Babaev A; O'Connor D; Zeller T; Dulas DD; Diaz-Cartelle J; Gray WA
Cardiovasc Intervent Radiol; 2021 Mar; 44(3):368-375. PubMed ID: 33225377
[TBL] [Abstract][Full Text] [Related]
24. The Zilver® PTX® Single Arm Study: 12-month results from the TASC C/D lesion subgroup.
Bosiers M; Peeters P; Tessarek J; Deloose K; Strickler S;
J Cardiovasc Surg (Torino); 2013 Feb; 54(1):115-22. PubMed ID: 23296421
[TBL] [Abstract][Full Text] [Related]
25. Full Drug-Eluting Stent Jacket: Two-Year Results of a Single-Center Experience With Zilver PTX Stenting for Long Lesions in the Femoropopliteal Arteries.
Phillips JA; Falls A; Kolluri R; Whipp A; Collins C; Mohir-Sadaai S; Reid B; Patil N; Alston M; Troyan M; Ansel GM
J Endovasc Ther; 2018 Jun; 25(3):295-301. PubMed ID: 29544372
[TBL] [Abstract][Full Text] [Related]
26. How should we manage thrombosis of Viabahn stent-graft? A case report focused on catheter-directed thrombolysis.
Kang WY; Campia U; Bernardo NL; Didier RJ; Negi SI; Kiramijyan S; Koifman E; Baker NC; Lipinski MJ; Escarcega RO; Torguson R; Waksman R
Cardiovasc Revasc Med; 2016 Mar; 17(2):134-7. PubMed ID: 26994746
[TBL] [Abstract][Full Text] [Related]
27. Long-term results of the heparin-bonded Viabahn stent graft in femoropopliteal TASC C and D lesions with a covered stent length of minimum 25 cm.
Uhl C; Dadras A; Reichmann F; Betz T; Zorger N; Toepel I; Steinbauer M
Vascular; 2019 Oct; 27(5):553-559. PubMed ID: 30917750
[No Abstract] [Full Text] [Related]
28. Atheromatous occlusive lesions of the popliteal artery treated with stent grafts: predictive factors of midterm patency.
Peidro J; Boufi M; Loundou Dieudonné A; Hartung O; Dona B; Vernet F; Alimi Y
Ann Vasc Surg; 2015; 29(4):708-15. PubMed ID: 25595105
[TBL] [Abstract][Full Text] [Related]
29. A single center experience of Zilver PTX for femoro-popliteal lesions.
Kang WY; Campia U; Didier RJ; Kiramijyan S; Koifman E; Negi SI; Lipinski MJ; Baker NC; Escarcega RO; Torguson R; Waksman R; Bernardo NL
Cardiovasc Revasc Med; 2016 Sep; 17(6):399-403. PubMed ID: 27496591
[TBL] [Abstract][Full Text] [Related]
30. Early Post-Registry Experience With Drug-Eluting Stents in the Superficial Femoral Artery.
Wooster M; Dansey K; Shames M
Vasc Endovascular Surg; 2016 Feb; 50(2):80-3. PubMed ID: 26912397
[TBL] [Abstract][Full Text] [Related]
31. Provisional Stenting Using the Zilver PTX Drug-Eluting Stent After Drug-Coated Balloon Angioplasty: Initial Experience From the Double Drug Dose "3D" Study.
Fanelli F; Cannavale A; Citone M; Santoni M; Gazzetti M; Falcone GM; Miele V
J Endovasc Ther; 2020 Feb; 27(1):34-41. PubMed ID: 31637956
[No Abstract] [Full Text] [Related]
32. Iliac Artery Stenting Combined with Ipsilateral Open Femoro-Popliteal Revascularization and Its Effect on Bypass Patency.
Piazza M; Squizzato F; Lepidi S; Menegolo M; Grego F; Antonello M
Ann Vasc Surg; 2017 Oct; 44():282-288. PubMed ID: 28479462
[TBL] [Abstract][Full Text] [Related]
33. Bare Metal Versus Paclitaxel-Eluting Stents for Long Femoropopliteal Lesions: Prospective Cohorts Comparison Using a Propensity Score-Matched Analysis.
Vent PA; Kaladji A; Davaine JM; Guyomarch B; Chaillou P; Costargent A; Quillard T; Gouëffic Y
Ann Vasc Surg; 2017 Aug; 43():166-175. PubMed ID: 28300676
[TBL] [Abstract][Full Text] [Related]
34. Long-Term Effectiveness of a Drug-Eluting Stent for Femoropopliteal In-Stent Restenosis: Subanalysis of the Zilver PTX Japan Post-Market Surveillance Study.
Sugimoto M; Komori K; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
J Endovasc Ther; 2021 Apr; 28(2):229-235. PubMed ID: 33084502
[TBL] [Abstract][Full Text] [Related]
35. Effectiveness of Zilver PTX eluting stent in TASC C/D lesions and restenosis.
Leopardi M; Houbballah R; Becquemin JP
J Cardiovasc Surg (Torino); 2014 Apr; 55(2):229-34. PubMed ID: 24670831
[TBL] [Abstract][Full Text] [Related]
36. Bare metal stent versus paclitaxel eluting stent for intermediate length femoropopliteal arterial lesions (BATTLE trial): study protocol for a randomized controlled trial.
Gouëffic Y; Kaladji A; Guyomarch B; Montagne C; Fairier D; Gestin S; Riche VP; Vent PA; Chaillou P; Costargent A; Patra P
Trials; 2014 Oct; 15():423. PubMed ID: 25359394
[TBL] [Abstract][Full Text] [Related]
37. Heparin-bonded stent-graft for the treatment of TASC II C and D femoropopliteal lesions: the Viabahn-25 cm trial.
Zeller T; Peeters P; Bosiers M; Lammer J; Brechtel K; Scheinert D; Rastan A; Noory E; Beschorner U
J Endovasc Ther; 2014 Dec; 21(6):765-74. PubMed ID: 25453876
[TBL] [Abstract][Full Text] [Related]
38. Treatment of femoropopliteal in-stent restenosis with paclitaxel-eluting stents.
Zeller T; Dake MD; Tepe G; Brechtel K; Noory E; Beschorner U; Kultgen PL; Rastan A
JACC Cardiovasc Interv; 2013 Mar; 6(3):274-81. PubMed ID: 23517839
[TBL] [Abstract][Full Text] [Related]
39. Impact of Chronic Renal Failure on Safety and Effectiveness of Paclitaxel-Eluting Stents for Femoropopliteal Artery Disease: Subgroup Analysis from Zilver PTX Post-Market Surveillance Study in Japan.
Ogawa Y; Yokoi H; Ohki T; Kichikawa K; Nakamura M; Komori K; Nanto S; O'Leary EE; Lottes AE; Saunders AT; Dake MD
Cardiovasc Intervent Radiol; 2017 Nov; 40(11):1669-1677. PubMed ID: 28488101
[TBL] [Abstract][Full Text] [Related]
40. Stent graft treatment for infra-inguinal arterial disease for either instent-restenosis and denovo lesions associated with very high rates of failure.
Golla MS; Acharji S; Paul TK; Madapathi P; Garcia LA
Catheter Cardiovasc Interv; 2018 May; 91(6):1130-1135. PubMed ID: 29214713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
